1. Women (18-70 years) with a stage I-III breast cancer diagnosis who have completed chemotherapy, immunotherapy and/or anti-HER2 agents.
2. Able to begin aerobic exercise within 12 weeks of the final chemotherapy, immunotherapy and/or anti-HER2 agents.
3. Sedentary by self-reporting inactivity (\<90 min of moderate or vigorous exercise per week)
4. Weight ≤154 kg
5. Willing to complete all study activities
6. Able to safely participate in moderate aerobic exercise.
You may not be if
1. Current pregnant and lactating patients. Must have completed lactation prior to study start.
2. Metastatic disease.
3. Diagnosed cardiovascular disease prior to the initiation of cancer therapy, as evidenced by cardiomyopathy (reduced regional or global left ventricular contractility), diastolic dysfunction grade 2 or above, symptomatic coronary artery disease, ejection fraction below 50%.
4. Non-English speaking
Clareo Health | Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer
